Mirror PR to Forgejo / mirror (pull_request) Waiting to run

Details

vida: extract claims from 2026-05-05-fda-oral-wegovy-approval-oasis4-jan2026

- Source: inbox/queue/2026-05-05-fda-oral-wegovy-approval-oasis4-jan2026.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

2026-05-05 08:19:51 +00:00

1.3 KiB

Raw Blame History

Oral Wegovy (Semaglutide Pill)

Type: GLP-1 receptor agonist, oral formulation
Manufacturer: Novo Nordisk
Status: FDA approved January 2026
Indication: Weight management in adults with obesity or overweight + ≥1 comorbidity; cardiovascular event risk reduction in adults with CVD + obesity/overweight

Clinical Profile

OASIS 4 Trial (Phase III, 64 weeks, n=307):

Weight loss: 16.6% with oral Wegovy + lifestyle intervention vs. 2.7% placebo
Serious adverse events: 3.9% treatment vs. 8.8% placebo (lower in treatment arm)
Common adverse reactions: nausea, vomiting, diarrhea
Efficacy comparable to injectable formulation for this population

Safety Label

Boxed warning: Thyroid C-cell tumor risk (standard GLP-1 class warning)
NO eating disorder warning in label
Suicidal behavior/ideation warning REMOVED in 2026 FDA review (no causal link found)
No eating disorder screening requirement in prescribing information

Market Significance

First oral GLP-1 formulation for weight management
Eliminates injection barrier, expanding addressable patient population
Manufacturing at North Carolina facilities
Launched January 2026

Timeline

2026-01-01 — FDA approval for weight management and cardiovascular risk reduction
2026-01-01 — Commercial launch with North Carolina manufacturing

1.3 KiB Raw Blame History